Similarly, elacridar, a third-generation P-gp inhibitor, effectively inhibited P-gp activity and reversed multidrug resistance in multiple cancer cell lines, thereby enhancing sensitivity to chemotherapeutics in vitro. The gene discussed is PGP; the disease is cancer.